Part 3/8:
The tension deepens as the CEO discovers unsettling news about a biotech project headed by a researcher named Bob. Not only has Bob been concealing major developments, but the project faces severe cybersecurity threats, indicating external interest in their revolutionary findings. As unexpected complications arise, the team scrambles to assess the validity and safety of Bob's results.
Beverly, a senior executive, confronts the possible fallout: “You have to decide fast,” she urges, caught between potential scientific advancement and the threat of disastrous implications if any aspect of their research goes awry.